Using a previously published protocol for anti-TGFβ therapy16, the antibodies were delivered via intraperitoneal injection (200 μg/mice) beginning 11 days after tumor implantation and continuing every other day for a total of eight doses (Fig. 3a). This evidence concerns the gene TGFB1 and neoplasm.